| Recruitment status | Completed |
| Unique ID issued by UMIN | C000000135 |
| Receipt No. | R000000200 |
| Official scientific title of the study | A combination phase II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancer. |
| Date of disclosure of the study information | 2005/09/08 |
| Last modified on | 2018/10/03 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | A combination phase II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancer. | |
| Title of the study (Brief title) | A combination phase II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancer. | |
| Region |
|
|
| Condition | |||
| Condition | Non-small cell lung cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate efficacy, toxicity, and survival of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Response Rate(according to RECIST criteria)
|
| Key secondary outcomes | Median survival time, 1-year survival,
Adverse events, Time to Progression, Quality of Life |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The treatment schedule included carboplatin AUC 4 on day 1, and gemcitabine 1000 mg/ m2 on days 1 and 8, every 3 weeks. (Below six courses more than three courses.)
|
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Patients with histologic or cytologic confirmation of locally advanced or metastatic NSCLC
2)Received either no prior chemotherapy were eligible 3)Measurable lesions 4)Age ≥ 70; 5)Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 6)Adequate organ function 7)Life expectancy for more than 3 months 8)Written informed consent |
|||
| Key exclusion criteria | 1)After thoracic irradiation
2)A case having severe infection and a serious complication 3)Requiring treatment pleural/ascites /pericardial effusion, 4)Interstitial pneumonia or active lung fibrosis on chest X-ray, 5)Symptomatic brain metastases 6)Double cancer 7)Others |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Nobuyuki Katakami |
| Organization | Institute of Biomedical Research and Innovation |
| Division name | Department of Translational Research Division of Integrated Oncology |
| Address | 2-2,Minatojima-Minamimachi,Chuo-ku,Kobe 650-0047 Japan |
| TEL | 078-304-5200 |
| Public contact | |
| Name of contact person | Takashi Nishimura |
| Organization | Kobe City General Hospital |
| Division name | Respiratory Medicine |
| Address | 4-6,Minatojima-Nakamachi,Chuo-ku,Kobe 650-0046 Japan |
| TEL | 078-302-4321 |
| Homepage URL | |
| t-nishi@kcgh.gr.jp | |
| Sponsor | |
| Institute | Institute of Biomedical Research and Innovation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000200 |